Ulf Meier-Kriesche

Company: Veloxis Pharmaceuticals

Job title: Chief Scientific Officer

Seminars:

Bridging Key Learnings of Surrogate Endpoint Development Across the CKD & Transplantation Communities 11:30 am

Developing a reasonably likely surrogate endpoint to allow for innovation in the kidney transplantation field Evaluating current endpoints used to measure success and outcomes of kidney transplantation Extracting applicable takeaways from advancements in phase 3 studies within the transplant fieldRead more

day: Day 1 Track 3 AM